… As such, our analyses comparing the effects of individual ALK inhibitors involved few trials,
and the findings may change with the publication of future trials. We were unable to assess …

… and network meta-analysis to indirectly compare the currently available ALK inhibitors. In …
progression-free survival in first-line treatment of ALK-positive NSCLC, followed by low-dose (…

… ALK inhibitor-related SAEs, especially lung toxicity. According to this meta-analysis, alxectinib
seems to be the safest ALK inhibitor. … on the related SAEs when prescribing ALK inhibitors. …

… them in overall survival and adverse events analysis. In terms of progression free survival, …
with ALK inhibitor-naive or untreated (ALK inhibitor-naive and chemotherapy-naive) ALK-…

… compare the efficacy and safety of different ALK inhibitors directly.9, 10 In the present
study, we attempted to compare each ALKi by using both single-arm and network meta-analyses. …

… and meta-analysis to assess the efficacy of ALK inhibitors compared to chemotherapy (ALK
vs… This analysis of ALK inhibitors compared to chemotherapy includes a heterogenous group …

… to conduct the quantitative meta-analysis. RESULTS: We found that ALK inhibitors significantly …
survival (PFS) of NSCLC patients, especially of ALK or ROS1 gene fusion-positive cases. …

… In this analysis, all four of the approved ALK inhibitors have shown acceptable … we analyzed
the AR of selected AEs between studies and amongst the 4 US FDA-approved ALK inhibitors…

… we performed a pooled analysis, including data from ALK positive NSCLC … analysis that
included data from ALK positive NSCLC patients with BMs receiving treatment with ALK inhibitors…

… of ALK inhibitors in NSCLC. Our result has demonstrated that ALK inhibitors are associated
with a significantly increased risk of liver toxicity based on the meta-analysis of 2418 patients …